Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia (Q34504188)

From Wikidata

Jump to navigation Jump to search

scientific article

edit

Language	Label	Description	Also known as
English	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

title

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

main subject

lymphocyte

0 references

leukemia

1 reference

based on heuristic

inferred from title

author

Andrew W. Roberts

object named as

Andrew W Roberts

series ordinal

1

0 references

William G Wierda

series ordinal

18

object named as

William G Wierda

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

author name string

Matthew S Davids

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

John M Pagel

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

Brad S Kahl

series ordinal

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

Soham D Puvvada

series ordinal

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

John F Gerecitano

series ordinal

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

Thomas J Kipps

series ordinal

7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

Mary Ann Anderson

series ordinal

8

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

Jennifer R Brown

series ordinal

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

Lori Gressick

series ordinal

10

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

Shekman Wong

series ordinal

11

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

Martin Dunbar

series ordinal

12

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

Ming Zhu

series ordinal

13

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

Monali B Desai

series ordinal

14

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

Elisa Cerri

series ordinal

15

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

Sari Heitner Enschede

series ordinal

16

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

Rod A Humerickhouse

series ordinal

17

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

John F Seymour

series ordinal

19

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

language of work or name

English

0 references

publication date

6 December 2015

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

published in

The New England Journal of Medicine

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

volume

374

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

issue

4

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

page(s)

311-322

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

cites work

Dose escalation methods in phase I cancer clinical trials

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk categories and refractory CLL in the era of chemoimmunotherapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The tumor lysis syndrome

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

miR-15 and miR-16 induce apoptosis by targeting BCL2

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Apoptosis therapy: driving cancers down the road to ruin

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Programmed anuclear cell death delimits platelet life span.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins

1 reference

stated in

PubMed

reference URL

https://pubmed.ncbi.nlm.nih.gov/26639348

retrieved

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

DOI

10.1056/NEJMOA1513257

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

PubMed publication ID

26639348

1 reference

stated in

Europe PubMed Central

PubMed publication ID

26639348

retrieved

2 August 2017

 

Sitelinks

Wikipedia(0 entries)

edit

Wikibooks(0 entries)

edit

Wikinews(0 entries)

edit

Wikiquote(0 entries)

edit

Wikisource(0 entries)

edit

Wikiversity(0 entries)

edit

Wikivoyage(0 entries)

edit

Wiktionary(0 entries)

edit

Multilingual sites(0 entries)

edit

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34504188&oldid=1980809372"